HIDEO MATSUZAKI

Prof. HIDEO MATSUZAKI

Research Center for Child Mental Development, University of Fukui
orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1999 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MTMichio Tamatani
Michio Tamatani
YCYong Ho Che
Yong Ho Che
HMHIDEO MATSUZAKI
HIDEO MATSUZAKI
SOSatoshi Ogawa
Satoshi Ogawa
HOHaruo Okado
Haruo Okado
MTMasaya Tohyama
Masaya Tohyama
Emerging data indicate that tumor necrosis factor (TNF) exerts a neuroprotective effect in response to brain injury. Here we examined the mechanism of TNF in preventing neuronal death in primary hippocampal neurons. TNF protected neurons against hypoxia- or nitric oxide-induced injury, with an increase in the anti-apoptotic proteins Bcl-2 and Bcl-x as determined by Western blot and reverse transcriptase-polymerase chain reaction analysis. Treatment of neurons with an antisense oligonucleotide to bcl-2 mRNA or that to bcl-x mRNA blocked the up-regulation of Bcl-2 or Bcl-x expression, respectively, and partially inhibited the neuroprotective effect induced by TNF. Moreover, adenovirus-mediated overexpression of Bcl-2 significantly inhibited hypoxia- or nitric oxide-induced neuronal death. To examine the possible involvement of a transcription factor, NFκB, in the regulation of Bcl-2 and Bcl-x expression in TNF-treated neurons, an adenoviral vector capable of expressing a mutated form of IκB was used to infect neurons prior to TNF treatment. Expression of the mutant NFκB completely inhibited NFκB DNA binding activity and inhibited both TNF-induced up-regulation of Bcl-2 and Bcl-x expression and neuroprotective effect. These findings indicate that induction of Bcl-2 and Bcl-x expression through NFκB activation is involved in the neuroprotective action of TNF against hypoxia- or nitric oxide-induced injury.

28 May 2008 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
YSYoshimoto Sekine
Yoshimoto Sekine
YOYasuomi Ouchi
Yasuomi Ouchi
GSGenichi Sugihara
Genichi Sugihara
NTNori Takei
Nori Takei
EYEtsuji Yoshikawa
Etsuji Yoshikawa
JCJean Lud Cadet
Jean Lud Cadet
Methamphetamine is a popular addictive drug whose use is associated with multiple neuropsychiatric adverse events and toxic to the dopaminergic and serotonergic systems of the brain. Methamphetamine-induced neuropathology is associated with increased expression of microglial cells that are thought to participate in either pro-toxic or protective mechanisms in the brain. Although reactive microgliosis has been observed in animal models of methamphetamine neurotoxicity, no study has reported on the status of microglial activation in human methamphetamine abusers. The present study reports on 12 abstinent methamphetamine abusers and 12 age-, gender-, and education-matched control subjects who underwent positron emission tomography using a radiotracer for activated microglia, [11C](R)-(1-[2-chlorophenyl]-N-methyl-N-[1-methylpropyl]-3-isoquinoline carboxamide) ([11C](R)-PK11195). Compartment analysis was used to estimate quantitative levels of binding potentials of [11C](R)-PK11195 in brain regions with dopaminergic and/or serotonergic innervation. The mean levels of [11C](R)-PK11195 binding were higher in methamphetamine abusers than those in control subjects in all brain regions (>250% higher;p< 0.01 for all). In addition, the binding levels in the midbrain, striatum, thalamus, and orbitofrontal and insular cortices (p< 0.05) correlated inversely with the duration of methamphetamine abstinence. These results suggest that chronic self-administration of methamphetamine can cause reactive microgliosis in the brains of human methamphetamine abusers, a level of activation that appears to subside over longer periods of abstinence.

1 January 2010 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
KNKazuhiko Nakamura
Kazuhiko Nakamura
YSYoshimoto Sekine
Yoshimoto Sekine
YOYasuomi Ouchi
Yasuomi Ouchi
MTMasatsugu Tsujii
Masatsugu Tsujii
EYEtsuji Yoshikawa
Etsuji Yoshikawa
NMNorio Mori
Norio Mori
Autism is a pervasive developmental disorder that is characterized by the behavioral traits of impaired social cognition and communication, and repetitive and/or obsessive behavior and interests.1 There is no established treatment or cure for the disorder. Recent population-based surveys showing that autism is more common than previously believed have aroused serious public concern worldwide.2 In addition, genome-wide linkage scans and copy-number analyses have revealed “hot spots” on several chromosomes.3-5 To clarify the pathophysiologic mechanism of autism, the neuroimaging approach is a fruitful method. In this study, we used positron emission tomography (PET) to focus on neurotransmitter alterations in the autistic brain.

12 March 2001 in The FASEB Journal
Verified
Journal Article
Closed access
HMHIDEO MATSUZAKI
HIDEO MATSUZAKI
MTMichio Tamatani
Michio Tamatani
AYAtsushi Yamaguchi
Atsushi Yamaguchi
KNKazuhiko Namikawa
Kazuhiko Namikawa
HKHiroshi Kiyama
Hiroshi Kiyama
MTMasaya Tohyama
Masaya Tohyama

27 May 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KSKatsuaki Suzuki
Katsuaki Suzuki
HMHIDEO MATSUZAKI
HIDEO MATSUZAKI
KIKeiko Iwata
Keiko Iwata
YKYosuke Kameno
Yosuke Kameno
CSChie Shimmura
Chie Shimmura
NMNorio Mori
Norio Mori
Accumulating evidence suggests that dysregulation of the immune system is involved in the pathophysiology of autism spectrum disorders (ASD). The aim of the study was to explore immunological markers in peripheral plasma samples from non-medicated subjects with high-functioning ASD. A multiplex assay for cytokines and chemokines was applied to plasma samples from male subjects with high-functioning ASD (n = 28) and matched controls (n = 28). Among a total of 48 analytes examined, the plasma concentrations of IL-1β, IL-1RA, IL-5, IL-8, IL-12(p70), IL-13, IL-17 and GRO-α were significantly higher in subjects with ASD compared with the corresponding values of matched controls after correction for multiple comparisons. The results suggest that abnormal immune responses as assessed by multiplex analysis of cytokines may serve as one of the biological trait markers for ASD.

1 February 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
AYAtsushi Yamaguchi
Atsushi Yamaguchi
MTMichio Tamatani
Michio Tamatani
HMHIDEO MATSUZAKI
HIDEO MATSUZAKI
KNKazuhiko Namikawa
Kazuhiko Namikawa
HKHiroshi Kiyama
Hiroshi Kiyama
MTMasaya Tohyama
Masaya Tohyama
Survival factors suppress apoptosis by activating the serine/threonine kinase Akt. To investigate the molecular mechanism underlying activated Akt's ability to protect neurons from hypoxia or nitric oxide (NO) toxicity, we focused on the apoptosis-related functions of p53 and caspases. We eliminated p53 by employing p53-deficient neurons and increased p53 by infection with recombinant adenovirus capable of transducing p53 expression, and we now show that p53 is implicated in the apoptosis induced by hypoxia or NO treatments of primary cultured hippocampal neurons. Although hypoxia and NO induced p53, treatment with insulin-like growth factor-1 significantly inhibited caspase-3-like activation, neuronal death and transcriptional activity of p53. These insulin-like growth factor-1 effects are prevented by wortmannin, a phosphatidylinositol 3-kinase inhibitor. Adenovirus-mediated expression of activated-Akt kinase suppressed p53-dependent transcriptional activation of responsive genes such as Bax, suppressed caspase-3-like protease activity and suppressed neuronal cell death with no effect on the cellular accumulation and nuclear translocation of p53. In contrast, overexpression of kinase-defective Akt failed to suppress these same activities. These results suggest a mechanism where Akt kinase activation reduces p53's transcriptional activity that ultimately rescues neurons from hypoxia- or NO-mediated cell death.